Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PfSPZ Vaccine Phase 1 in Malaria-Experienced Adults
NCT02663700Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Apr 2016
- Primary completion
- Dec 2018
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Sanaria PfSPZ Vaccine in malaria (5 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Occurrence of Grade 3 unsolicited adverse events (AEs) considered related to vaccination, Occurrence of serious adverse events (SAEs) at any point during the study period and 2 more. Started Apr 2016; status: completed.
02
Drugs
Sanaria PfSPZ Vaccine
03
Conditions
malaria
Beyond the preview
Go deeper on NCT02663700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02663700.